TLSA (Tiziana Life Sciences) ROA %: -182.24% (As of Dec. 2025)


TLSA Tiziana Life Sciences Ltd TLSA
30 GF Score
Price $1.15
! 2 Warning Signs
View Full Analysis

What is Tiziana Life Sciences ROA %?

Tiziana Life Sciences TLSA +2.23% 30 ROA % is -182.24% as of Dec. 2025. GuruFocus rates TLSA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Tiziana Life Sciences ranks worse than 89.6% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Tiziana Life Sciences's annualized Net Income for the quarter that ended in Dec. 2025 was $-25.60 Mil. Tiziana Life Sciences's average Total Assets over the quarter that ended in Dec. 2025 was $14.05 Mil. Therefore, Tiziana Life Sciences's annualized ROA % for the quarter that ended in Dec. 2025 was -182.24%.

The historical rank and industry rank for Tiziana Life Sciences's ROA % or its related term are showing as below:

TLSA' s ROA % Range Over the Past 10 Years
Min: -201.17   Med: -99.56   Max: -39.2
Current: -140.42

During the past 13 years, Tiziana Life Sciences's highest ROA % was -39.20%. The lowest was -201.17%. And the median was -99.56%.

TLSA's ROA % is ranked worse than
89.6% of 1423 companies
in the Biotechnology industry
Industry Median: -32.9 vs TLSA: -140.42

Tiziana Life Sciences  (NAS:TLSA) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-25.598/14.046
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-25.598 / 0)*(0 / 14.046)
=Net Margin %*Asset Turnover
=N/A %*0
=-182.24 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Tiziana Life Sciences ROA % Related Terms


Tiziana Life Sciences ROA % Historical Data

* Premium members only.

The historical data trend for Tiziana Life Sciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tiziana Life Sciences ROA % Chart

Tiziana Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.20 -40.89 -91.52 -101.10 -161.82

Tiziana Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -122.61 -80.42 -129.61 -80.80 -182.24

TLSA vs DTIL, MIST, EQ: ROA % Comparison

For the Biotechnology subindustry, Tiziana Life Sciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tiziana Life Sciences ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's ROA % distribution charts can be found below:

* The bar in red indicates where Tiziana Life Sciences's ROA % falls into.


TLSA
30GF Score
Tiziana Life Sciences Ltd TLSA
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tiziana Life Sciences ROA % Calculation

Tiziana Life Sciences's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-18.431/( (11.284+11.495)/ 2 )
=-18.431/11.3895
=-161.82 %

Tiziana Life Sciences's annualized ROA % for the quarter that ended in Dec. 2025 is calculated as:

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-25.598/( (16.597+11.495)/ 2 )
=-25.598/14.046
=-182.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -182.24% mean?
Tiziana Life Sciences (TLSA) has a ROA % of -182.24% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Tiziana Life Sciences and its competitors. According to the industry distribution chart, Tiziana Life Sciences ranks #1275 out of 1423 companies in the Biotechnology industry, placing it in the top 89.6%.
Is Tiziana Life Sciences' ROA % too high?
Tiziana Life Sciences' current ROA % is -182.24%. Based on the distribution chart, Tiziana Life Sciences ranks #1275 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tiziana Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Tiziana Life Sciences' ROA % compare to DTIL and MIST?
According to the Biotechnology industry distribution chart, Tiziana Life Sciences ranks #1275 out of 1423 companies for ROA %. This places Tiziana Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Tiziana Life Sciences and its competitors. Tiziana Life Sciences's current ROA % is -182.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tiziana Life Sciences stock overvalued right now?
Tiziana Life Sciences (TLSA) has a current ROA % of -182.24%. The current ROA % is -182.24%. Tiziana Life Sciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Tiziana Life Sciences (TLSA), the current ROA % is -182.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tiziana Life Sciences Business Description

Other Exchanges 0RP:Germany
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM 11
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
30GF Score

Get the complete analysis for TLSA

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price